Patients with uncontrolled inter-current illnesses which in the opinion of the investigator will interfere with the ability to undergo therapy including chemotherapy are excluded
Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator can consult the study chair or study co-chairs for uncertainty in this regard
Any malabsorption problem that, in the investigator's opinion, would prevent adequate absorption of the study drug
Presence of concomitant intercurrent illness, or any condition which in the opinion of the Investigator, would compromise safe participation in the study, e.g. active severe infection, unstable angina pectoris, new onset of exacerbation of a cardiac arrhythmia.
Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
Major bowel surgery which in the opinion of the Investigator should exclude the patient
Any other active malignancy other than melanoma that, in the opinion of the investigator, would interfere with study participation (for treatment phase)
Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs.
Any other condition which the Investigator believes would make participation in the study not acceptable
Patient must not have a co-morbid condition(s) that, in the opinion of the investigator, prevent safe treatment
Any history of a medical condition or a concomitant medical condition that, in the opinion of the investigator, would compromise the subject's ability to safely complete the study
Any other medical or psychiatric condition that in the opinion of the investigator would make the study therapy unsafe for the patient
Any condition, in the opinion of the investigator, that compromises compliance with study requirements
History of any major disease that might interfere with safe protocol participation, as determined by the investigator
Significant allergy to a pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient
Women with skin conditions such as psoriasis, fungal infections, keloids etc., or tattoos and/or piercings, which in the opinion of the Investigator, would interfere with absorption of the IP.
Subject has a known gastrointestinal disorder that in the opinion of the treating investigator is concerning for malabsorption of oral medications
Any other medical or social condition that, in the opinion of the investigator, would not permit the patient to complete the study or sign informed consent
PROCUREMENT EXCLUSION CRITERIA: Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation
Patients with a chronic uncontrolled medical condition that, in the opinion of the principal investigator, precludes them from participation
Any significant psychiatric disease, medical or other condition, which in the opinion of the principal investigator could prevent adequate informed consent or compromise participation in the clinical trial
Patients with a known history of drug abuse or any chronic neurologic, psychiatric, endocrine, metabolic, immunologic, hepatic or renal disease (including a history of hemolytic uremic syndrome) that in the opinion of the Investigator would adversely affect study participation.
Patients with a \currently active\ second malignancy that, in the opinion of the principal investigator, will interfere with patient participation, increase patient risk, shorten survival to <  year, or confound data interpretation
Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug
Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
Patients must NOT have any concurrent medical condition that, in the opinion of the PI or designee, would prevent the patient from undergoing protocol-based therapy; patients with a primary immunodeficiency/ bone marrow failure syndrome are excluded from this trial
Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular or hepatic disease, within the last  months that, in the opinion of the investigator, would adversely affect his/her participation in the study.
Patients with rapidly progressing disease in the opinion of the principal investigator
Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual
Any condition which, in the opinion of the investigator, would prevent full participation in this trial (including the long-term follow-up), or would interfere with the evaluation of the trial endpoints
Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his/her designee, would prevent adequate informed consent.
The presence of a medical or psychiatric condition that, in the opinion of the principal investigator, makes the patient inappropriate for inclusion in this study
Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of azacitidine that in the opinion of the investigator would adversely affect his/her participating in this study.
Any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment
Subjects must NOT have any concurrent medical condition that, in the opinion of the protocol PI or designee, would prevent the patient from undergoing protocol-based therapy; subjects with a primary immunodeficiency/bone marrow failure syndrome are excluded from this trial
Subjects must NOT have any concurrent medical condition that, in the opinion of the protocol PI or designee, would prevent the patient from undergoing protocol-based therapy; subjects with a primary immunodeficiency/bone marrow failure syndrome are excluded from this trial
Subject has any other significant medical or psychiatric history that in the opinion of the investigator would adversely affect participation in this study
Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
Has any severe concurrent disease, infection, or comorbid condition that renders the patient inappropriate for enrollment in the opinion of the investigator
Investigator's opinion of subject's probable noncompliance or inability to understand the trial and/or give adequate informed consent;
Participant has chronic respiratory disease that requires continuous oxygen, or significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, any other medical condition or known hypersensitivity to any of the study medications including excipients of LDAC that in the opinion of the investigator would adversely affect his/her participating in this study.
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator
Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion, makes him/her an unreliable trial subject, unlikely to complete the trial, or unable to comply with the protocol procedures.
Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
Subjects should be in otherwise satisfactory health in the opinion of the Investigator;
No serious disease or condition that, in the opinion of the investigator, would compromise the patients ability to participate in the study
Patients positive for hepatitis C are permitted if controlled with medication, in the opinion of the investigator
Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
Eligible for therapy for the lymphoid malignancy which has a high likelihood of a curative result in the opinion of the investigator
Subject has any medical or psychiatric condition that, in the opinion of the Investigator, may compromise the subject's ability to participate in this study
Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
Patients with a significant psychiatric disease, who in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe will be excluded
Any severe concurrent disease, infection or comorbid condition that renders the patient inappropriate for enrollment in the opinion of the investigator or interferes with the patient's ability to participate in the study requirements
Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent
Patient, in the opinion of the investigator, is likely to be poorly compliant
A co-morbid condition that, in the Investigator's opinion, renders the subject at high risk for treatment complications.
Any major medical illnesses or psychiatric impairments that in the treating physicians opinion will prevent administration or completion of protocol therapy (which may include patients who are elderly, debilitated, or malnourished persons and/or those with renal, hepatic or adrenal insufficiency)
Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence with study requirements or confound the interpretation of study results
History of psychiatric disorder or any other condition which may compromise compliance with transplant protocol or expose patient to unnecessary risk as determined by principal investigator or lead associate investigator
Any concurrent or past medical condition that, in the opinion of the investigator, would exclude the subject from participation
Requirement for treatment in the opinion of the investigator.
Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participating in the study.
Patient does NOT have any concurrent medical condition that, in the opinion of the protocol PI or designee, would prevent the patient from undergoing protocol-based therapy; patients with a primary immunodeficiency/bone marrow failure syndrome are excluded from this trial
Significant cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal or autoimmune conditions that in the opinion of the investigator places the subject at an unacceptable risk as participant in this trial
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
Patients who exhibit any significant concurrent, uncontrolled medical or psychiatric condition that in the opinion of the investigator would compromise the patient's ability to tolerate this treatment are NOT eligible for participation
Patients with other medical conditions or concomitant medications that in the opinion of the principal investigator may interfere with the therapeutic treatment.
Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patients ability to tolerate this treatment
Patients with other significant disease or disorders that, in the investigator's opinion, would exclude the patient from the study
Any co-morbidity or condition of sufficient severity to limit full compliance with the protocol per assessment by the investigator
Subjects who have other conditions which in the opinion of the investigator contraindicate the receipt of HSV or indicate subjects inability to follow protocol requirements
Any co morbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol
Patients who in the opinion of the principal investigator are poor psychiatric or medical risks are not eligible
Has any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject. Additional Exclusion Criteria for Cohort :
No other illness that in the opinion of the investigator would exclude the subject from participating in the study
Presence of any co-morbid or an uncontrolled medical condition (e.g. diabetes mellitus), which in the opinion of the investigator would increase the potential risk to the subject. Investigator should liaise with the Medical Monitor where there is uncertainty as to the eligibility of a patient
History of sensitivity to any of the study medications, or metabolite thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation CARDIAC MAGNETIC RESONANCE (CMR) SCANNING
Subjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment or survival
Has any history or medical condition, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:
Any evidence of other disease or any concomitant medical or psychiatric problems which in the opinion of the Investigator would prevent completion of treatment
History of clinically significant medical condition that, in the opinion of the investigator, would adversely affect participation in this study.
Any condition medical or psychosocial that in the opinion of the investigator would hinder compliance
Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
Any medical condition that, in the opinion of the investigator, would exclude the patient from participating in this study and treatment plan.
Patient has a foreign body which in the opinion of the treating investigator could be difficult to manage in case of infection
The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent  months at the time of consent.
Patients for whom it is not in the best interest to participate in the study, in the opinion of the treating investigator
Patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug
Any concurrent or past medical condition that, in the opinion of the Investigator, would exclude the subject from participation or any psychosocial conditions that would hinder study compliance or follow-up, at the discretion of the Investigator
Any underlying medical condition, psychiatric condition or social situation that in the opinion of the investigator would compromise study administration as per protocol or compromise the assessment of adverse events (AEs)
Any underlying medical condition, psychiatric condition or social situation that in the opinion of the investigator would compromise study administration as per protocol or compromise the assessment of adverse events (AEs)
Active uncontrolled infection or major concurrent illness which in the opinion of the investigator would render the patient unsafe to proceed with the study
No gastro-intestinal condition, that in the opinion of the treating physician or the principal investigator significantly limits oral absorption
Any condition which the investigator's opinion deems the patient ineligible
Any medical condition which in the opinion of the investigator puts the patient at risk of potentially serious complications while on this therapy
Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated
Any medical or psychiatric illness, which in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment or limit compliance with study requirements
Presence of a significant psychiatric disease, which in the opinion of the principal investigator or his designee, would prevent adequate informed consent or render immunotherapy unsafe or contraindicated
Subjects must have recovered from major infections and/or surgical procedures and, in\n             the opinion of the investigator, not have a significant active concurrent medical\n             illness precluding protocol treatment.
Any medical or psychiatric illness, which, in the opinion of the principal investigator, would compromise the patients ability to tolerate this treatment
Subjects with any other medical condition, which in the opinion of the investigator would compromise the results of the study by deleterious effects of treatment
Subjects with any other medical condition, which in the opinion of the investigator would compromise the results of the study by deleterious effects of treatment
Any other significant disease or other clinical findings which in the opinion of the investigator would prevent study entry
Subjects who, in the opinion of the Investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of serious comorbid condition(s) (e.g., uncontrolled cardiac or respiratory disorders).
c) History of other malignancy that in the Investigator's opinion would not affect the determination of study treatment effect
Patients may not have any other medical condition or reason, in that investigator's opinion, makes the patient unstable to participate in a clinical trial
Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:
Any other medical condition that, in the opinion of the Investigator, would adversely affect the subject's participation in the study.
Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.
Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator, such as but not limited to:
No other illness that in the opinion of the investigator would exclude the subject from participating in the study
In the opinion of the investigator the patients must:
Medical condition or organ system dysfunction which, in the investigator opinion, could interfere with absorption or metabolism of ibrutinib
Any reason that, in the opinion of the Investigator, contraindicates that the patient participates in the study
Any other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
History of another malignancy that in the opinion of the investigator may compromise the outcome of the study
Any reason why, in the opinion of the investigator, the patient should not participate.
Patients who have any current or prior medical condition that can interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator or the sponsor's medical monitor.
Subjects must be stable and, in the opinion of the investigator, be expected to complete  week treatment period.
Clinically significant psychiatric disease which, in the opinion of the PI or sub-investigator (I), would render immunotherapy and its potential sequelae unsafe or compliance with procedural requirements unlikely
Any other medical condition that in the opinion of the investigator may interfere with a subject participation in, or compliance with, the study
Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs.
Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the Principal Investigator. Intraoperative Eligibility Criteria:
No serious disease or condition that, in the opinion of the investigator, would compromise the patients ability to participate in the study
The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent  months at the time of consent; investigator discretion is allowed
Participant has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study.
Patient, in the opinion of the investigator, is likely to be poorly compliant
Other major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy
The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent  months at the time of consent; investigator discretion is allowed
In the opinion of the investigator, patient must be able to receive at least  cycles of treatment
Any medical condition which, in the opinion of the investigator, puts the patient at risk of potentially serious complications while on study treatment
Patients must have recovered from any major infections and/or surgical procedures and, in the opinion of the investigator, not have significant active medical illness precluding protocol treatment or survival
Medical, social, or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance with study procedures.
Has any disease or condition that, per protocol or in the opinion of the investigator, might affect:
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have significant active concurrent medical illnesses precluding study treatment
Any condition which, in the opinion of the investigator, would prevent full participation in this trial (including the long-term follow-up), or would interfere with the evaluation of the trial endpoints
the patient is less than  years of age but has significant comorbid condition(s) that are, in the opinion of the investigator, likely to have a negative impact on tolerability of HDT-SCT
Other past or current malignancy unless in the opinion of the investigator it does not contraindicate participation in the study
Significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, pulmonary or hepatic disease, that in the opinion of the investigator, would adversely affect his/her participation in the study.
Significant concurrent medical or psychiatric illness which, in the opinion of the principal investigator would interfere with trial participation
Any laboratory abnormalities, which in the opinion of the investigator, may put the subject at risk if participating in the study; for example:
In the opinion of the investigator, the patient is felt not to be appropriate for the study
Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment in the investigator's opinion.
Subject has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.
Subject has a significant history of renal, neurologic, psychiatric, pulmonary, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the Investigator would adversely affect his/her participating in this study.
Any other medical condition that in the opinion of the principal investigator would compromise the ability to deliver or evaluate study drug
Serious concurrent illness, which in the opinion of the investigator or an authorized physician sub-investigator would interfere with participation in this clinical study
Any medical or psychiatric condition that in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment
Any medical condition which would, in the investigator's opinion, compromise the patient's ability to mount an immune response, renders the patient a poor candidate for this trial or could confound the results of the study
No serious disease or condition that, in the opinion of the investigator, would compromise the subject's ability to participate in the study
Medical or psychiatric condition which in the opinion of the protocol chairman would compromise the patient's ability to tolerate this protocol
Uncontrolled intercurrent illness (i.e., active infection) or concurrent condition that, in the opinion of the Investigator, would interfere with the study endpoints or the patient's ability to participate
The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study
Has, in the Investigator's opinion, any medical condition that makes the subject a poor candidate for the investigational procedure, or interferes with the interpretation of study results.
Is actively participating in another investigational clinical study which, in the Investigator's or Sponsor's opinion, would interfere in this study.
Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator, such as but not limited to:
Uncontrolled intercurrent illness (i.e., active infection ? Grade ) or concurrent condition that, in the opinion of the Investigator, would interfere with the study endpoints or the subject's ability to participate.
The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the subject inappropriate for inclusion in this study.
Any malabsorption condition that in the opinion of the investigator would significantly impact drug absorption
Any reason why, in the opinion of the investigator, the patient should not participate
Any malabsorption condition that in the opinion of the investigator would significantly impact drug absorption
Any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation.
Significant, concurrent, uncontrolled medical condition which, in the opinion of the investigator, may interfere with patient participation in the study.
The patient has a prior or concurrent malignancy that in the opinion of the investigator, presents a greater risk to the patients health and survival, than of the MCL, within the subsequent  months at the time of consent; investigator discretion is allowed
Any other medical condition that, in the opinion of the principal investigator (PI), may interfere with a subject's participation in or compliance with the study
History of concomitant medical conditions or infectious diseases that, in the opinion of the investigator, would compromise the participant's ability to safely complete the study.
Any other medical condition that, in the opinion of the PI, may interfere with a subject's participation in or compliance with the study
Patients who have serious intercurrent medical illness which in the opinion of the investigator would compromise the patient's ability to tolerate this therapy
Patient has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the subject including but not limited to uncontrolled infection, heart failure, pulmonary hypertension, etc.
Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product.
Patient has a foreign body which in the opinion of the treating investigator could be difficult to manage in case of infection (e.g. prosthetic hip).
Concomitant intercurrent illness, or any condition which in the opinion of the Investigator, would compromise safe participation in the study, e.g. active severe infection, unstable angina pectoris, new onset of exacerbation of a cardiac arrhythmia
Any concurrent medical condition that, in the opinion of the Investigator, would complicate or compromise compliance with the study or the well-being of the subject
Any other condition that in the investigator's opinion would not make the subject a good candidate for the clinical study,
Subjects who, in the Investigator's opinion, have any medical condition that makes the subject a poor candidate for the investigational procedure, or interferes with the interpretation of study results.
The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study.
Any condition that in the opinion of the investigator would cause the subject to be unable to participate or tolerate the protocol regimen
Ongoing or recent history of any other uncontrolled and/or clinically significant systemic disease or condition which, in the Investigator's medical opinion, should exclude participation in the study
Concurrent use of complementary or alternative medicines that in the opinion of the principal investigator would confound the interpretation of toxicities and/or antitumor activity of the study drug
Disease that requires treatment based on the Investigator's opinion (e.g., meets GELF criteria)
Patients with a co-morbid condition(s) that, in the opinion of the investigator, prevents safe surgery/biopsy procedure
Have a history of thrombocytopenia with complications including hemorrhage or bleeding >= grade  using NCI CTCAE v.,  June  that required medical intervention or any hemolytic condition or coagulation disorders that would make participation unsafe in the opinion of the investigator
Has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures
Active infection or antibiotics within one-week prior to study, including unexplained fever; any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the principal investigator, could prevent adequate informed consent or compromise participation in the clinical trial
Any other condition including but not limited to major co-morbidities, which in the opinion of the investigator would render the patient ineligible.
Any other clinically significant medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol compliance
The risk of rapidly fatal illness and death within  hrs, or any concomitant condition not related to ventilator-associated pneumonia that, in the opinion of the investigator, precludes completion of study evaluations and the course of therapy
Any medical or psychiatric illness which, in the opinion of the principal investigator, would compromise the patient's ability to tolerate this treatment regimen
In the opinion of the Investigator, subjects with a low chance of survival during the first  days of treatment.
In the opinion of the investigator the protocol treatment is appropriate for the participant
Donor must not have any medical condition, which, in the opinion of the clinical investigator, would interfere with his/her evaluation.
Subjects who, in the opinion of the investigator, are not likely to survive beyond  hours from Baseline.
Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; the investigator should consult the study chair
Any reason why, in the opinion of the investigator, the patient should not participate
In the investigator's opinion and in compliance with the Institution Hematology Tumor Board's guidances, the patient should not be eligible for any additional chemotherapy treatment before the ASCI treatment.
Any significant psychiatric disease, medical intervention, or other condition, which in the opinion of the principal investigator or co-investigators, could prevent adequate informed consent or compromise participation in the clinical trial
Any reason why, in the opinion of the investigator, the patient should not participate
Patients who are severely underweight in the opinion of the investigator
Patients with a condition that, in the opinion of the investigator, would interfere with the absorption of oral medication will be excluded from the study
Patient has any other condition that, in the opinion of the investigator, may impact the absorption of oral medications
PATIENTS: Existence of co-morbid disease, which in the opinion of the investigator prohibits participation in the protocol
Have a history of thrombocytopenia with complications including hemorrhage or bleeding of ?Grade  per NCI CTCAE v. that required medical intervention or have any hemolytic condition or coagulation disorder that would make participation unsafe in the opinion of the investigator.
Has a clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, infectious, metabolic, neurologic, psychologic, or pulmonary disorder or any other condition, including excessive alcohol or drug abuse, or secondary malignancy, that may interfere with study participation in the opinion of the investigator.
Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk
Any other condition that, in the opinion of the investigator, may impact the absorption of oral medications
Any concurrent co-morbid illness and/or infection which in the opinion of the investigators could make the patient an inappropriate subject for the above trial
Has been diagnosed with/exhibits any mental neurological disorder/disease/condition that would prevent participation in the study in the opinion of the investigator
Presence of medical co-morbidities, which, in the opinion of the investigator complicates the surgical procedure or would require additional hospital stay
Patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study; examples of this would be hearing loss or neuropathy which would prevent tolerance to cisplatin, and paclitaxel administration; the investigator should feel free to consult the Study Chair or Study Co-Chairs for uncertainty in this regard
Medical, psychiatric condition which in the investigators opinion will affect the successful completion of study
Known previous or concomitant serious illness (other than advanced cancer with metastatic bone disease) or medical condition, such as, HIV, significant gastrointestinal disease, or cardiovascular event that in the opinion of the investigator may worsen and/or interfere with participation in the study
History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.
Subject has evidence, in the opinion of the Investigator, of either on-going systemic or pleural infection.
Subject has any clinical condition, diagnosis, or social circumstance that, in the opinion of the Investigator, would mean participation in the study would be contraindicated.
Acute or chronic medical disorder that, in the opinion of the investigator or medical monitor, may prevent the subject from completing participation in the study
Any serious, uncontrolled comorbidity or condition that an Investigator believes would interfere with the intent of the study or would make participation not in the best interest of the patient Intraoperative Exclusion Criteria
Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data
Other illness that in the opinion of the investigator would exclude the patient from participating in this study
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
Have any medical disease or condition that, in the opinion of the site principal investigator is a contraindication to study participation; this includes any chronic medical condition, defined as persisting  months (defined as  days) or longer, that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subjects successful completion of this study
Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
Presence of any major medical condition which, in the opinion of the investigator, precludes participation in the study
Any condition which, in the opinion of the investigator, would prevent full participation in this trial (including follow-up), or would interfere with the evaluation of the trial endpoints
Any physical or psychological condition that, in the opinion of the investigator, would post unacceptable risk to the patient or raise concern that the patient would not comply with protocol procedures
Any other significant acute or chronic diseases that in the investigator's opinion would exclude the subject from the trial
Concurrent illness which in the opinion of the investigators would compromise either the patient or the integrity of the data
Any other condition that, in the opinion of the investigator, makes the patient or donor ineligible for the study
Any other condition which, in the opinion of the investigator, makes the patient ineligible for the study Inclusion Criteria Donor:
Subjects with any other condition that would contraindicate participation, as determined by the Investigator.
Medical comorbidities that in the opinion of the investigator limits the patients ability to complete this study
Significant medical or psychiatric history which would make the participant a poor protocol candidate, in the opinion of the principal investigator, for any aspect of study participation including metformin, unsupervised exercise program or dietary behavior change
Any condition, medical or psychosocial, that in the opinion of the principal investigator would hinder compliance
Patients with psychiatric or other conditions rendering them incapable of participating in informed consent or the requirements of this protocol or other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator may significantly interfere with study compliance.
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Any condition which, in the opinion of the investigator precludes the patient from completion of the study procedure
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
Any condition which, in the opinion of the investigator, might interfere with study objective
Any reason which, in the opinion of the investigator, adds additional risk to the patient
DONOR: Any condition which, in the opinion of the investigator, might interfere with study objective
Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Any additional medical condition, serious intercurrent illness or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study performance or interpretation
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
Clinically relevant hepatic, neurological, pulmonary, ophthalmological, endocrine, renal, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult, or that would put the subject at risk by participating in the study in the opinion of the Investigator.
Any other condition which in the opinion of the investigator would interfere with successful completion of this clinical trial.
Does the subject have any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance
Presence of any additional medical condition such as inter-current illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
Any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data
Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
In the opinion of the investigator, the patient is felt not to be appropriate for the study
Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:
Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual
History of a prior intolerable toxicity, in the opinion of the investigator from another B-cell lymphoma (BCL)- family protein inhibitor study.
